Rapt
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 5.0m | 3.8m | 1.5m | - | - | - | 12.3m |
| % growth | - | (24 %) | (60 %) | - | - | - | - |
| EBITDA | (53.2m) | (69.2m) | (85.8m) | (126m) | (111m) | (101m) | (101m) |
| % EBITDA margin | (1055 %) | (1815 %) | (5619 %) | - | - | - | (820 %) |
| Profit | (52.9m) | (69.2m) | (83.8m) | (117m) | (105m) | (123m) | (219m) |
| % profit margin | (1049 %) | (1815 %) | (5490 %) | - | - | - | (1778 %) |
| EV / revenue | 74.1x | 234.9x | 276.9x | - | - | - | -15.9x |
| EV / EBITDA | -7.0x | -12.9x | -4.9x | -5.5x | 0.7x | 0.9x | 1.9x |
| R&D budget | 45.5m | 57.0m | 67.1m | 101m | - | - | - |
| R&D % of revenue | 902 % | 1494 % | 4393 % | - | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$9.0m | Series C | ||
$11.2m | Series D | ||
$3.4m | Seed | ||
N/A | Acquisition | ||
N/A | Seed | ||
$37.0m | Series C | ||
| N/A | N/A | IPO | |
* | $50.0m | Private Placement VC | |
* | N/A | N/A | Post IPO Equity |
| Total Funding | AUD171m | ||
Related Content
Recent News about Rapt
EditRAPT Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative oral therapeutics aimed at targeting key drivers of the immune system. The company's mission is to transform the treatment of cancer and inflammatory diseases through cutting-edge science. RAPT Therapeutics primarily serves patients suffering from cancer and inflammatory conditions, offering them new hope through advanced medical treatments. Operating in the biopharmaceutical market, the company leverages its expertise in immunology to create therapies that intelligently target specific pathways within the immune system.
The business model of RAPT Therapeutics revolves around research and development (R&D) of novel drug candidates, which are then advanced through clinical trials. The company generates revenue through partnerships, licensing agreements, and potential future sales of its proprietary drugs once they receive regulatory approval. RAPT Therapeutics also attracts investment opportunities, which help fund its ongoing R&D efforts and clinical trials.
Key clients include healthcare providers, research institutions, and pharmaceutical companies interested in innovative treatments for cancer and inflammatory diseases. The company aims to improve and empower countless lives by offering effective and targeted therapeutic solutions.
Keywords: biopharmaceutical, oral therapeutics, immune system, cancer treatment, inflammation, clinical trials, drug development, immunology, R&D, partnerships.